Navigation Links
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Date:1/4/2008

- Studies to investigate safety and efficacy in treatment of multi-drug

resistant infections -

NEW HAVEN, Conn., Jan. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a biopharmaceutical company focused on the development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the enrolment of the first patients in two separate Phase 2 clinical trials. The studies will evaluate the safety and efficacy of RX-1741 in the treatment of Community-Acquired Pneumonia (CAP), and separately in the outpatient treatment of Uncomplicated Skin and Skin Structure Infections (uSSSI). RX-1741 is the Company's first antibiotic program developed using its proprietary technology platform.

RX-1741 is an oxazolidinone antibiotic that exhibits activity against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms, and has demonstrated both greater spectrum and potency of activity than the currently marketed product of the same class, Zyvox(R) (linezolid). Discovered using proprietary knowledge of the three dimensional structure of a key area of the ribosome, the 50S subunit, Rib-X believes that RX-1741 will demonstrate a high level of effectiveness against resistant microbes.

"These two studies represent important milestones for Rib-X," said Dr. Susan Froshauer, President and CEO of Rib-X Pharmaceuticals. "RX-1741 is the first of many compounds that Rib-X intends to design and develop in response to the alarming growth of drug resistant microbial pathogens found both in the hospital and in the community. This MRSA-active agent will satisfy a critical need for physicians and their patients because current treatment options are very limited, particularly for orally active agents," said Dr. Froshauer.

CAP Study Design

The CAP study is a Phase 2, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
2. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
4. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
5. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
9. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SoundConnect , an award ... proud to announce the strategic additions of implementation, ... Boston, Charleston and Atlanta offices. SoundConnect’s organizational ... for hosted solutions, collaboration and mobility that improve ... , SoundConnect was founded in 2004, with the ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... 29, 2014   Sequenom, Inc. (NASDAQ: ... innovative genetic analysis solutions, and Mayo Medical Laboratories ... in the United States , have ... and applications. "We have great appreciation for ... and we welcome the opportunity to partner with the ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... Enlarge and Worsen Over Time , , CHICAGO, June 15 ... enlarged leg veins as a cosmetic issue without recognizing they can ... their doctors for other health symptoms, Vein Clinics of America is ... from affecting their everyday routine. , , To view the ...
... 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... appointment of Scott Peterson, Ph.D., as Vice President, ... Dr. Peterson will be responsible for overseeing those ... will support the advancement of the Company,s pipeline ...
... June 15 Congressional Quarterly presents a 360-degree look ... follow-on versions of biotech drugs. This CQ Forum will ... groups, and leading researchers regarding the complex structures of ... Will the availability of these products save money for ...
Cached Biology Technology:Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 2Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 3Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 4Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... multitude of cells types. Researchers would like to understand how ... cells that make up the organs and other structures of ... chains of sugars that dangle from proteins on surfaces of ... San Diego, has created synthetic molecules that can stand in ... to direct the process, they report in the Journal ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to John Ellis for his pioneering contributions to biochemistry, ... Professor in the Department of Biological Sciences at the ... of the Springer book How Science Works: Evolution. Dr. ... London, and completed postdoctoral studies at Oxford University. In ...
... centuries-old religious ceremony of an indigenous people in southern Mexico ... of fish, according to researchers from Texas A&M University. ... World, the Zoque people of southern Mexico would venture each ... Cueva del Azufre to implore their deities for a bountiful ...
... most frustrating problems faced by doctors who treat pancreatic cancer ... 38,000 people in the United States die of the disease ... For almost three decades, scientists and physicians have known ... virtually all pancreatic cancers, making it an important target for ...
Cached Biology News:Moved by religion: Mexican cavefish develop resistance to toxin 2Moved by religion: Mexican cavefish develop resistance to toxin 3UNC team discovers promising target for new pancreatic cancer treatments 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: